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Abstract
Aims/hypothesis The aim of the study was to examine the association between lipoprotein-associated phospholipase A2
(Lp-PLA2) activity levels and incident diabetic retinopathy and change in retinopathy grade.
Methods This was a cohort study of diabetic participants with serum collected at baseline and routinely collected diabetic retinal
screening data. Participants with type 2 diabetes from the GoDARTS (Genetics of Diabetes Audit and Research in Tayside
Scotland) cohort were used. This cohort is composed of individuals of white Scottish ancestry from the Tayside region of
Scotland. Survival analysis accounting for informative censoring by modelling death as a competing risk was performed for
the development of incident diabetic retinopathy from a disease-free state in a 3 year follow-up period (n = 1364) by stratified Lp-
PLA2 activity levels (in quartiles). The same analysis was performed for transitions to more severe grades.
Results The hazard of developing incident diabetic retinopathy was 2.08 times higher (95%CI 1.64, 2.63) for the highest quartile
of Lp-PLA2 activity compared with the lowest. Higher Lp-PLA2 activity levels were associated with a significantly increased risk
for transitions to all grades. The hazards of developing observable (or more severe) and referable (or more severe) retinopathy
were 2.82 (95% CI 1.71, 4.65) and 1.87 (95% CI 1.26, 2.77) times higher for the highest quartile of Lp-PLA2 activity compared
with the lowest, respectively.
Conclusions/interpretation Higher Lp-PLA2 levels are associated with increased risk of death and the development of incident
diabetic retinopathy, as well as transitions to more severe grades of diabetic retinopathy. These associations are independent of
calculated LDL-cholesterol and other traditional risk factors. Further, this biomarker study shows that the association is tempo-
rally sensitive to the proximity of the event to measurement of Lp-PLA2.
Keywords Diabetic complications . Electronic medical records . Epidemiology . Lipids/lipoproteins . Microvascular disease .
Retinopathy
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Abbreviations
DARTS Diabetes Audit and Research in Tayside Scotland
DBP Diastolic blood pressure
DME Diabetic macular oedema
DR(0–4) Diabetic retinopathy (grade)
GoDARTS Genetics of Diabetes Audit and Research in
Tayside Scotland
LDLc LDL-cholesterol
Lp-PLA2 Lipoprotein-associated phospholipase A2
SBP Systolic blood pressure
Introduction
Diabetic retinopathy is a leading cause of vision loss and
blindness in the working age population (20–74 years of
age) of most developed countries [1]. It was found to occur
in 35% of people with diabetes based on a meta-analysis of
multiple studies [2]. The increasing number of individuals
with diabetes worldwide suggests that diabetic retinopathy is
likely to be a growing contributor to vision loss and associated
functional impairment in the future [3].
Risk factors associated with diabetic retinopathy include
age, race/ethnicity, longer duration of diabetes, insulin depen-
dence, younger age of diabetes onset, higher HbA1c, insulin
treatment and higher blood pressure [4–10]. Studies have also
shown that hyperlipidaemia, hyperglycaemia and hyperten-
sion contribute to the pathogenesis of diabetic retinopathy
[11–14]. Smoking is generally not considered a risk factor;
however, at least one study found a significant association
between smoking and diabetic macular oedema (DME), a
condition that progresses from retinopathy, in people with
type 1 diabetes [15]. For decades, the management paradigm
for diabetic retinopathy and DME had been early detection,
optimal glycaemic control, blood pressure control, laser pho-
tocoagulation and surgery, if necessary [3, 16, 17]. More re-
cently, intravitreally administered medications such as anti-
vascular endothelial growth factor (VEGF) agents and corti-
costeroids have shown beneficial effects [16, 18–20].
However, a number of high-risk participants are not identified
by current methods of screening [3].
Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a
vascular-specific, proinflammatory enzyme that binds to plas-
ma lipoproteins (~70–80% to LDL-cholesterol [LDLc], the
rest to HDL-cholesterol). Packard et al first demonstrated, in
the West of Scotland Coronary Prevention Study
(WOSCOPS) trial, that Lp-PLA2 activity is associated with
increased risk of coronary events [21]. Subsequent studies
have confirmed that Lp-PLA2 activity is prospectively associ-
ated with increased risk of coronary heart disease, indepen-
dent from risk attributable to circulating lipid levels [22, 23].
Lp-PLA2 has been postulated to play an important role in
diabetes-induced vascular leakage, which may cause the
breakdown of the inner blood–retinal barrier that is observed
in early and more advanced stages of retinopathy and DME.
Studies with Lp-PLA2 inhibitors, darapladib and SB-435495
(GlaxoSmithKline, King of Prussia, PA, USA), have provided
evidence of reduced leakage across the blood–retinal barrier in
diabetic participants and a rat model of diabetes, respectively
[24, 25]. In addition, darapladib has been shown to reduce
leakage across the blood–brain barrier in diabetic and hyper-
cholesteraemic pig models [26].
The purpose of this study is to explore whether variation in
Lp-PLA2 activity measured in serum samples from a diabetic
•
•
•
•
•
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population is associated with subsequent incidence of, or pro-
gression from less to more severe, retinopathy.
Methods
Basic information about the study cohort
Diabetes Audit and Research in Tayside Scotland (DARTS) is
an integrated clinical management system linking all clinical
events of individuals with type 2 diabetes in the Tayside re-
gion of Scotland and provides complete continuity of care
from general physicians, diabetes specialists and population
screening services. GoDARTS (Genetics of DARTS) is a sub-
cohort study of individuals fromDARTSwho have provided a
sample of blood for genetic studies and have given consent for
linking genetic data to study complications of diabetes, the
clinical data for which is continually updated from the elec-
tronic medical record [27]. Between 2004 and 2007, partici-
pants with type 2 diabetes were recruited (together with non-
diabetic controls, who were not included in this study). A
serum sample was also collected from every participant at
recruitment, and a series of characteristics was measured.
Recruitment was treated as the baseline for this study. A co-
hort study in GoDARTS with a 3 year follow-up period was
used to evaluate the primary objective: to test the association
between Lp-PLA2 activity levels (measured at baseline) and
incident diagnosis of retinopathy, as well as progression of
retinopathy grade.
Measurement of exposure: Lp-PLA2 activity
The exposure of interest was Lp-PLA2 activity level, mea-
sured in serum samples taken at baseline. The biobanked se-
rum samples for this population were analysed for Lp-PLA2
activity using the CAM colorimetric assay (diaDexus, San
Francisco, CA, USA) [28]. Note that Lp-PLA2 mass was nei-
ther measured nor analysed. The activity assay was performed
at the Immunoassay Biomarker Core Laboratory, University
of Dundee. The diaDexus assay was provided directly from
the manufacturer to the laboratory. The intra-assay %CV (n =
36) was 5.8%. The inter-assay (assay to assay) %CV (n = 8)
was 7.6%. The duplicate intra-assay %CV of those partici-
pants measured in duplicate (n = 134) was 3.0% (range 0%–
18.6%).
Measurement of main outcome: diabetic retinopathy
For retinopathy, data were acquired from the Scottish National
Diabetic Eye Screening Service. The severity of retinopathy
was coded as per the Scottish Diabetes Retinal Grading
Scheme (www.ndrs-wp.scot.nhs.uk/wp-content/uploads/
2013/04/Grading-Scheme-2007-v1.1.pdf), and are denoted
as follows: disease-free (DR0), mild (DR1), observable
(DR2), referable (DR3) and proliferative (DR4). Retinal
screening in Tayside, Scotland has been undertaken since
1990, initially with Polaroid images, progressing to digital
images in 2000 [10]. The Tayside diabetic retinopathy screen-
ing protocol has been described previously [29] and the
GoDARTS cohort has been used previously by Liu et al to
examine risk factors for the progression of diabetic retinopa-
thy [10]. This cohort provides a high-resolution longitudinal
dataset for the study of retinal disease progression. Data in-
cludes stages of retinopathy, recorded separately for both eyes,
and dates. The eye with more advanced retinopathy stage was
used for analysis. The screening data used in this study are
from the years 1990 to 2011. The most recent screening data
prior to baseline was used to establish the prevalent retinopa-
thy stage. The primary outcome variables were time to first
occurrence in the record of DR1, DR2, DR3 or DR4 (i.e.
incident retinopathy). Time to DR2 was assessed as the time
from baseline until first visit where grade DR2 was recorded,
and similarly for times to DR3 or DR4. However, this study
does not examine the association of Lp-PLA2 with DME, as
the screening data does not contain information specific to
DME status.
Competing risk: association of Lp-PLA2 with death
in GoDARTS
Previous studies of diabetic and non-diabetic participants have
demonstrated that Lp-PLA2 activity levels are strongly asso-
ciated with incident coronary heart disease and mortality [23].
In GoDARTS, death during the follow-up period was deter-
mined from the administrative records of the General
Registrar Office, which holds details of deaths throughout
Scotland. Time from baseline to death (for the full cohort)
was analysed using the Cox proportional hazards model, with
age and sex as covariates, and with quartiles of baseline Lp-
PLA2 activity levels as the exposure (see electronic supple-
mentary material [ESM] Table 1 and ESM Fig. 1).
Exclusion and inclusion criteria
Exploratory analyses suggested that the modelling assump-
tions were sensitive to the temporal proximity of death and
retinopathy events to the time of serum collection and Lp-
PLA2 measurement. Therefore, a follow-up period of 3 years
was chosen to reduce the potential for bias, while maintaining
follow-up for enough incident and progression events to ac-
crue. The main analyses reported considered only outcomes
that occurred within a 3 year follow-up period after baseline
for each participant. Participants with no diabetic retinopathy
assessment, and who also did not die within this follow-up
period, were excluded completely from the main analyses.
The effect of these exclusions (which made the main analysis
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sample size substantially smaller than the full cohort size) was
assessed using sensitivity analyses. Since participants with
DR4 at baseline could not be analysed for further disease
progression, these participants were also excluded from all
analyses. Of the full cohort of n = 6731 participants, n = 684
were excluded because they had DR4 at baseline (Table 1), a
further n = 4667 were excluded from the main analyses be-
cause they had inadequate follow-up (neither death nor reti-
nopathy assessment within 3 years), and finally 16 individuals
were excluded from the analyses as they had inadequate base-
line covariate information. Hence 1364 participants were in-
cluded in the study cohort for analyses.
Statistical methods
Lp-PLA2 measurements were used as a linear trait for associ-
ation testing with baseline covariates and divided into quar-
tiles for cumulative incidence modelling of survival analysis.
Means and SDs of Lp-PLA2 activity are presented. Diabetic
retinopathy grades were the outcome event and were treated as
a binary (yes or no) variable for survival analyses. Baseline
variables were selected for potential inclusion as covariates,
based on known associations with diabetic retinopathy.
Variables considered as potential covariates in the analyses
were an individual’s retinopathy status prior to baseline (esti-
mated from the last visit at or prior to serum collection date),
and participant age, sex, prior duration of diabetes, BMI, cal-
culated LDLc, HbA1c, smoking status, systolic and diastolic
blood pressure (SBP and DBP), eGFR, use of statins and use
of diabetes-controlling medication (all measured at baseline).
The association with baseline covariates was assessed using
univariate linear regression. Variables found to be significant-
ly associated in univariate regressions were then tested in sur-
vival analyses, and non-significant variables were eliminated
from the final model. Survival analyses adjusted for compet-
ing risk of death were conducted with Lp-PLA2 activity levels
(in quartiles) using a cumulative incidence model. Results of
survival analyses are presented as the omnibus test for the Lp-
PLA2 variable, HR and 95% CI. The results of the main ef-
fects (unadjusted) and final (adjusted) models on Lp-PLA2
hazards are shown in Table 2. Individuals with missing data
were excluded on a per-analysis basis.
The cumulative incidence graphs presented are unadjusted,
and demonstrate the main effect of Lp-PLA2 quartiles on the
Table 1 Baseline demographics of the full GoDARTS cohort (n = 6731) and study cohort (n = 1364)
Variable Baseline population (n = 6731) Study cohort (n = 1364)
Association with Lp-PLA2 Association with Lp-PLA2
β estimate (95% CI) β estimate (95% CI)
Lp-PLA2, nmol min
−1 ml−1 121.2 ± 34.8 – 113.4 ± 32.5 –
Age, years 65 ± 11 −0.41 (−0.48, −0.34) 67 ± 11 −0.38 (−0.45,−0.30)***
Sex (% women) 44 −13.87 (−15.51, −12.23)*** 41 −14.00 (−15.51, −12.23)***
Smokers (% ever smokers) 62 4.33 (2.61, 6.06)* 63 4.33 (2.61, 6.05)***
Statin users (% statin users) 90 −9.42 (−12.00, −6.85)*** 91 −9.63 (−12.60, −6.57)***
Diabetes-controlling medication users (% users) 75 −4.58 (−6.40, −2.75) 81 −4.81 (−6.77, −2.86)**
Duration of diabetes, years 7 ± 6 −0.001 (−0.0015, −0.0007) 9 ± 7 −0.002 (−0.0015, −0.0007)***
BMI, kg/m2 31 ± 6 −0.12 (−0.25, −0.98)* 31 ± 6 −0.16 (−0.30, −0.02)***
Baseline clinical data
Calculated LDLc, mmol/l 2.09 ± 0.77 19.70 (18.72, 20.67)*** 2.10 ± 0.80 20.00 (18.54, 20.57)***
HbA1c, mmol/mol 58 ± 16 0.17 (0.12, 0.22)*** 59 ± 18 0.16 (0.11, 0.22)***
HbA1c, % 7.5 ± 1.45 1.83 (1.26, 2.40)*** 7.60 ± 1.60 1.83 (1.26, 2.40)***
SBP, mmHg 142 ± 19 −0.07 (−0.11, −0.30)* 143 ± 20 −0.08 (−0.12, −0.03)
DBP, mmHg 77 ± 12 0.28 (0.21, 0.35)*** 75 ± 12 0.27 (0.20, 0.34)***
eGFR, ml min−1 [1.73 m]−2 85 ± 20 0.05 (0.005, 0.099)* 85 ± 20 0.05 (0.006, 0.1)*
Baseline diabetic retinopathy status (reference group DR0)
DR0: no diabetic retinopathy, n (%) 3207 (50.30) −1.44 (−2.10, −0.80)*** 548 (40.20) −1.44 (−2.09, −0.80)***
DR1: mild, n (%) 1496 (23.50) 464 (34.00)
DR2: moderate, n (%) 968 (15.20) 345 (25.30)
DR3: severe, n (%) 16 (0.30) 7 (0.50)
DR4: proliferative, n (%) 684 (10.70) –
Data are mean ± SD, % or n (%) Associations were tested using univariate linear regression, with Lp-PLA2 as the outcome
***p < 0.001, **p < 0.01, *p < 0.05
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development and progression of retinopathy. All HRs of Lp-
PLA2 use the lowest quartile of Lp-PLA2 activity as the ref-
erence. All statistical analyses were conducted using SAS 9.4
(SAS institute, Cary, NC, USA).
Ethics approval and participant consent
The Tayside Medical Ethics Committee has approved the
GoDARTS study and informed consent was obtained for
all participants. The participants have consented to
research on their samples and data related to diabetes, its
treatment and related conditions. They have also
consented to the fact that the studies may involve collab-
orative studies with commercial companies and that the
participants will not benefit financially from such collab-
orations. Neither the University of Dundee research team
nor GlaxoSmithKline had access to personally identifiable
information. All event level data is provided to the
University of Dundee research team in anonymised fash-
ion by the Data Linkage team of the Health Informatics
Centre at the University of Dundee.
Results
Baseline associations
All diabetic participants in GoDARTS with available serum
were assayed for Lp-PLA2 activity. Measured Lp-PLA2 activ-
ity levels were approximately normally distributed (presented
in Fig. 1a) and were therefore analysed as an untransformed,
continuous variable for baseline analysis. The mean (SD) Lp-
PLA2 activity level was 121 (35) nmol min
−1 ml−1. The ob-
served quartiles were Q1 ≤ 97.2, Q2 ≤ 117.3, Q3 ≤ 140.7 and
Q4 ≤ 377.9 nmol min−1 ml−1, which were used to divide the
participants into equal sized groups for survival analyses.
Their sex, age, usage of diabetes-controlling medica-
tion, usage of statins, smoking status, duration of diabetes,
HbA1c, LDLc levels, eGFR and SBP were all associated
with their Lp-PLA2 activity levels. The distribution of Lp-
PLA2, and the association of sex, BMI, LDLc and HbA1c
with Lp-PLA2 in the population is presented in Fig. 1. Lp-
PLA2 levels stratified by sex showed significantly different
levels; women have lower levels than men (Fig. 1b). The
mean (SD) Lp-PLA2 levels amongst women was 114 (35)
nmol min−1 ml−1 compared with 127 (35) nmol min−1 ml−1
for men. The correlation of Lp-PLA2 activity levels with
BMI, LDLc, HbA1c and eGFR at baseline are also shown
in Fig. 1c–f, respectively. The only notable correlation was
with LDLc, which showed a strong linear relationship with
Lp-PLA2, with a correlation coefficient of 0.44.
The association of these potentially confounding variables
with Lp-PLA2 is presented for the study population and the
full GoDARTS cohort (Table 1). Variables showed similar
associations in the study population compared with the full
GoDARTS cohort; however, the study cohort were on average
2 years older, had type 2 diabetes for 2 years longer, a higher
proportion were medicated for type 2 diabetes, and a lower
proportion were disease-free (DR0) at baseline. This suggests
that the study cohort had more severe disease at baseline and
were therefore more likely to be screened regularly for pro-
gression during follow-up.
Table 2 Association of predictors and covariates included in each
analysis
Variable HR 95% CI p value
Development of incident retinopathy from disease-free statea
Main effects model
Lp-PLA2 Q2 vs Q1 1.33 1.08, 1.64 <0.01
Lp-PLA2 Q3 vs Q1 1.56 1.28, 1.90 <0.0001
Lp-PLA2 Q4 vs Q1 1.52 1.24, 1.86 <0.0001
Final modelb
Lp-PLA2 Q2 vs Q1 1.52 1.21, 1.91 <0.001
Lp-PLA2 Q3 vs Q1 1.72 1.37, 2.17 <0.001
Lp-PLA2 Q4 vs Q1 2.08 1.64, 2.63 <0.001
Progression to observable or more severe retinopathy from lower gradesc
Main effects model
Lp-PLA2 Q2 vs Q1 1.86 1.29, 2.77 <0.01
Lp-PLA2 Q3 vs Q1 2.33 1.59, 3.42 <0.0001
Lp-PLA2 Q4 vs Q1 2.21 1.46, 3.331 <0.001
Final modeld
Lp-PLA2 Q2 vs Q1 1.96 1.23, 3.00 <0.01
Lp-PLA2 Q3 vs Q1 2.71 1.75, 4.20 <0.001
Lp-PLA2 Q4 vs Q1 2.82 1.71, 4.65 <0.001
Progression to referable or proliferative retinopathy from lower gradese
Main effects model
Lp-PLA2 Q2 vs Q1 1.76 1.23, 2.50 <0.01
Lp-PLA2 Q3 vs Q1 1.81 1.26, 2.60 <0.01
Lp-PLA2 Q4 vs Q1 1.83 1.25, 2.70 <0.01
Final modelf
Lp-PLA2 Q2 vs Q1 1.64 1.13, 2.37 <0.01
Lp-PLA2 Q3 vs Q1 1.98 1.34, 2.92 <0.01
Lp-PLA2 Q4 vs Q1 1.87 1.26, 2.77 <0.01
a DR0 to DR1 or higher, n = 1013
b Lp-PLA2 omnibus test for variable:Waldχ
2 , 38.2 (df = 3) p value = 3 ×
10−8
c DR0 or DR1 to DR2 or higher, n = 1241
d Lp-PLA2 omnibus test for variable: Wald χ
2 , 23.6 (df = 3) p value =
1.5 × 10−53
e DR0, DR1 or DR2 to DR3 or higher, n = 1364
f Lp-PLA2 omnibus test for variable: Wald χ
2 , 16.8 (df = 3) p value =
2.8 × 10−3
Q, quartile
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Association of Lp-PLA2 with death
In agreement with results from previous large meta-analyses
including both diabetic and non-diabetic participants [23], Lp-
PLA2 activity levels were strongly associated with death in the
diabetic population of the GoDARTS cohort for whom Lp-
PLA2 activity was measured (n = 6731). This is demonstrated
in ESM Fig. 1 and ESM Table 1 as an increased risk of death
for participants in the highest two quartiles of Lp-PLA2 levels
compared with the lowest. The hazard of death for those in the
highest Lp-PLA2 quartile was approximately one and a half
times that for participants in the lowest quartile (HR 1.45, 95%
CI 1.24, 1.68; p < 0.001). Hence, when analysing the associ-
ation between Lp-PLA2 activity levels and time to progres-
sion, censoring at death would violate the non-informative
censoring assumption required for standard survival analyses
such as Cox regression [30]. Therefore, a competing risk sur-
vival analysis [31] was used to analyse the association with
incident diabetic retinopathy and progression to more severe
stages.
Survival analyses
Association of Lp-PLA2 activity with incident diabetic retinop-
athy For this analysis, a cohort of 1013 individuals who had
no observable retinopathy (DR0) at baseline were included.
Of these, 676 individuals progressed to any retinopathy grade
(mild retinopathy: DR1, or higher) in the 3 year follow-up
period. In the same cohort there were 143 deaths prior to
any record of progression, and 194 individuals who were cen-
sored (alive and without progression).
As shown in Table 2, there was a progressive trend of
increased risk across the quartiles. The hazards of developing
incident retinopathy were 1.52, 1.72 and 2.08 for Lp-PLA2
quartiles 2, 3 and 4, respectively, compared with quartile 1.
The omnibus test of hazard across the quartiles of Lp-PLA2
activity was highly significant (p = 3 × 10−8). This analysis
was adjusted for sex, diabetes-controlling medication, use of
statins, HbA1c levels, systolic blood pressure, LDLc levels
and the age of the individual at baseline and was therefore
independent of traditional risk factors for diabetic retinopathy.
The accompanying cumulative incidence plot (Fig. 2a) is
unadjusted and shows the increased hazards of incident reti-
nopathy for Lp-PLA2 activity quartiles relative to the lowest
quartile (light blue line).
The GoDARTS study largely recruited at the time of the
participants’ annual diabetes review, which accounts for the
evident increase in retinopathy diagnosis at the 1 year mark,
coinciding with the next annual review after recruitment.
Association of Lp-PLA2 activity with progression to observ-
able or more severe diabetic retinopathy from lower grades
For this analysis, a cohort of 1241 individuals who had no
observable retinopathy or had mild retinopathy (DR0 or
DR1) at baseline were included. Of these, 209 individuals
progressed to more severe retinopathy (grade DR2 or higher)
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Fig. 1 (a) Baseline distribution of
Lp-PLA2 activity
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in the 3 year follow-up period. In the same cohort there were
432 participants who died prior to progression, and 600 indi-
viduals who were censored.
The hazards of developing moderate or more severe reti-
nopathy were 1.96, 2.71 and 2.82 for Lp-PLA2 activity quar-
tiles 2, 3 and 4, respectively, compared with quartile 1
(Table 2). The overall omnibus test for association across the
quartiles of Lp-PLA2 activity was highly significant (p =
1.5 × 10−5) and independent of traditional risk factors for dia-
betic retinopathy. This analysis was adjusted for diabetes-
controlling medication, HbA1c levels, SBP, LDLc levels and
the age of the individual and was therefore independent of
traditional risk factors.
The accompanying cumulative incidence plot (Fig. 2b) is
unadjusted and shows the increased hazards of developing
moderate or more severe forms of retinopathy by Lp-PLA2
quartiles compared with the lowest quartile (light blue line).
Association of Lp-PLA2 activity with progression to referable
or proliferative diabetic retinopathy from lower grades For
this analysis, the cohort of 1364 individuals who had no ob-
servable retinopathy, or had mild or observable retinopathy
(DR0, DR1, or DR2) at baseline were included. Of these,
461 individuals progressed to more severe retinopathy (grade
DR3 or higher) in the 3 year follow-up period. In the same
cohort there were 435 participants who died prior to progres-
sion, and 468 individuals who were censored.
The hazards of developing severe retinopathy were 1.64,
1.98 and 1.87 for Lp-PLA2 quartiles 2, 3 and 4 respectively
compared with quartile 1 (Table 2). The omnibus test of asso-
ciation across the quartiles of Lp-PLA2 activity levels was
highly significant (p = 2.8 × 10−3) and independent of tradi-
tional risk factors for diabetic retinopathy. This analysis was
adjusted for grade at baseline, diabetes-controlling medica-
tion, HbA1c levels, SBP, smoking status and the age of the
individual and therefore independent of traditional risk
factors.
The cumulative incidence plot (Fig. 2c) is unadjusted and
shows the increased hazards of progressing to referable or
proliferative retinopathy from lower grades by Lp-PLA2 quar-
tiles compared with the lowest quartile (light blue line).
ESM Table 2 shows HRs for Lp-PLA2 quartiles for each
analysis with every level of adjustment.
Sensitivity analyses for extended follow-up period
When considering the longer follow-up period of 5 years, the
association with Lp-PLA2 activity with incident diabetic reti-
nopathy was attenuated (HR 1.17, 1.14 and 1.26 for Lp-PLA2
quartiles 2, 3 and 4 respectively) with only the highest quartile
remaining significant (p = 0.03). Further details are provided
in ESM Table 3 and ESM Fig. 2. Therefore, it was decided to
limit our analysis to a 3 year follow-up period.
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Fig. 2 (a) Cumulative incidence plot of the hazards of incident diabetic
retinopathy for Lp-PLA2 activity quartiles, main effects model. (b)
Cumulative incidence plot of the hazards of progression to observable
or more severe retinopathy by Lp-PLA2 activity quartiles, main effects
model. (c) Cumulative incidence plot of hazards of progression to refer-
able or proliferative retinopathy by Lp-PLA2 activity quartiles, main ef-
fects model. Light blue line with crosses, lowest quartile (quartile 1) of
Lp-PLA2 activity; red line with triangles, quartile 2; brown line with
circles, quartile 3; green line with crosses, highest quartile (quartile 4).
Symbols denote events
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Discussion
As a result of the association of Lp-PLA2 with increased risk
for cardiovascular disease [23] we observe that high Lp-PLA2
activity levels are prospectively associated with an increased
risk of death in this cohort of individuals with type 2 diabetes.
All analyses for retinopathy outcomes were therefore adjusted
for this factor by using a competing risk analysis, which di-
rectly estimates the effect of Lp-PLA2 activity separately on
the event of interest (incidence or progression) and the com-
peting event (death), and also allows non-informative censor-
ing for participants when neither event occurred before the
end of the study period.
Lp-PLA2 activity was an independent predictor for devel-
opment of incident diabetic retinopathy. Analysing progres-
sion to any grade resulted in a similar finding. The association
of baseline Lp-PLA2 activity with incidence and progression
of diabetic retinopathy was highly statistically significant and
was independent of LDLc and other traditional risk factors
including HbA1c, blood pressure, lipid-controlling medica-
tion, diabetes-controlling medication, age and sex. A progres-
sive trend of risk by Lp-PLA2 activity quartiles can be ob-
served in the first two analyses (incident diabetic retinopathy
and progression to observable or more severe grades), where
every subsequent quartile confers additional risk to the devel-
opment of retinopathy or the progression to more severe
stages.
Previously, well-established risk factors for diabetic reti-
nopathy included duration of diabetes and poor glycaemic
control and blood pressure. This study presents evidence that
a proinflammatory enzyme is associated with both the inci-
dence of diabetic retinopathy, as well as progression to more
severe stages. Crucially, this is a potential therapeutic target,
for which existing antagonists could be repurposed.
The conclusions of these results are supported by the
Bradford Hill causal criteria for epidemiological studies
[32]: the associations are robust (statistically significant
and do not change drastically with the addition of covar-
iates), consistent (across all analyses, albeit not externally
validated) and show specificity to Lp-PLA2 in models
adjusted for potential confounders. Additionally, the re-
sults are temporally valid since the measurement of expo-
sure (Lp-PLA2) precedes the outcome (retinopathy) and
the association is sensitive to the time between the two,
with attenuation on increasing time from the date of the
activity measure (it is easier to predict the immediate fu-
ture). The association shows a biological gradient (higher
quartiles of Lp-PLA2 levels are associated with increased
hazards of incidence and progression). There is a plausi-
ble mechanism for the association as being due to vascu-
lar leakage, and experimental evidence (from animal stud-
ies) supports the hypothesis that inhibition of Lp-PLA2
results in reduced leakage across the blood–retinal and
blood–brain barriers [24–26]. The findings of this study
will have to be replicated externally in other cohorts.
Limitations of this study include the fact that serum
was collected at a random point in the disease progression
for each individual, so it was not consistent by disease
state. In addition, 10% of the cohort had proliferative
retinopathy at the time of serum collection, hence data
from these participants were uninformative in a prospec-
tive analysis of incidence. A further 70% of the full co-
hort had inadequate follow-up for the main analyses, with
neither death nor retinopathy assessment in 3 years after
baseline. However, this would be an interesting area for
exploration, given the evidence presented here. Sensitivity
analyses using longer follow-up periods benefited from
larger sample size (fewer participants with inadequate
follow-up) but potentially introduced other biases, such
as increased competing risks and a longer gap between
measurement of Lp-PLA2 and occurrence of outcome. It
is possible that the association between Lp-PLA2 activity
and onset or progression of diabetic retinopathy is con-
founded (by factors unknown or unmeasured at baseline)
or is biased (e.g. by another unidentified competing risk,
or by another mechanism of informative censoring). The
nature of an observational epidemiological study means
that it is impossible to rule out the possibility of such
confounding or biases.
However, complete records of retinopathy screening data
for all individuals in a large cohort of individuals with diabetes
is a powerful resource. A further strength is the rich set of
clinical and questionnaire baseline data that can be used to
adjust for known or suspected confounders, and outcome data
that can be used to adjust for competing risks.
Interpretation
Lp-PLA2 activity levels are shown to be associated with an
individual’s risk of developing diabetic retinopathy.
Individuals with Lp-PLA2 activity levels above the median
have a very high risk of progressing to more severe stages.
Since this relationship appears to be independent of traditional
risk factors and, specifically, independent of baseline LDLc
levels, these data are consistent with the hypothesis that sys-
temic inhibition of Lp-PLA2 activity may be a good therapeu-
tic target in the prevention of this complication of diabetes.
Application
This is a population cohort of white Scottish individuals,
with many variables captured using routinely collected
health record information. The study population is repre-
sentative of the diabetic population in Scotland undergo-
ing routine screening [10]. The duration of type 2 diabetes
is an important risk factor when considering the
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extrapolation of these results; diabetic retinopathy is more
prevalent when duration of type 2 diabetes is longer than
10 years [2]. This is reflected in the duration of type 2
diabetes in the study population, which, with the addition
of 3 years of follow-up, is on average 12 years.
Furthermore, the rate of adherence to annual, recommend-
ed screens for those with pre-existing retinopathy was
reported to be as low as 61%, while the rate of screening
for those with long duration of type 2 diabetes was 57%
[33]. Overall there is evidence to suggest that adherence
to annual screens range between 34% and 65% [3, 9,
33–35]. This suggests that the drop-off rate noted with
the 3 year follow-up exclusion criteria is reflective of
real-world consumption of healthcare in a population with
type 2 diabetes. Further, association characteristics of Lp-
PLA2 activity are similar to those reported elsewhere
[21–23]. Therefore the generalisability of the study to a
population of European descent with routine access to
healthcare is likely to be high. On the basis of previous
observations in animal and human studies it is unlikely
that the ethnicity of the cohort would limit the
generalisability of this study.
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